Most Read Articles
Roshini Claire Anthony, 3 days ago

Individuals with moderate-to-severe plaque psoriasis may reap better long-term improvements in the severity of their condition when treated with guselkumab over secukinumab, according to findings of the phase III ECLIPSE* trial presented at the recent Inflammatory Skin Disease Summit (ISDS 2018) held in Vienna, Austria.

Jairia Dela Cruz, 11 Jan 2019
Use of standard-dose aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) appears to confer protection against the risk of endometrial cancer in overweight and obese women, according to a meta-analysis.
Elvira Manzano, 4 days ago
Treatment with two investigational, oral JAK inhibitors may be beneficial in individuals with moderate‐to‐severe alopecia areata (spot baldness), an autoimmune disease that can cause a lot of anxiety, according to an ongoing phase II study.
2 days ago
Discontinuing the use of tyrosine kinase inhibitors (TKIs) in the treatment of patients with chronic myeloid leukaemia appears to be feasible in real-life clinical practice in the context of close molecular monitoring, a study reports.

Original New Drug Application Approvals by US FDA (1 - 15 November 2017)

15 Nov 2017
New drug applications approved by US FDA as of 1 - 15 November 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Vyzulta (latanoprostene bunod ophthalmic solution), 0.024%
  • Active Ingredient(s): Latanoprostene bunod
  • Strength: 0.024
  • Dosage Form: Ophthalmic solution
  • Company: Bausch and Lomb Inc
  • Approval Date: November 02, 2017
  • Submission Classification: Type 1 - New Molecular Entity
  • Indication(s): Indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension
  • Approved Label: 11/02/2017 (PDF)

BORTEZOMIB
  • Active Ingredient(s): Bortezomib
  • Strength: 3.5 mg
  • Dosage Form: Injectable;injection
  • Company: Fresenius Kabi USA
  • Approval Date: November 06, 2017
  • Submission Classification: Type 5 - New Formulation or New Manufacturer
  • Indication(s): Indicated for
    • treatment of patients with multiple myeloma
    • treatment of patients with mantle cell lymphoma who have received at least 1 prior therapy
  • Approved Label: 11/06/2017 (PDF)

PREVYMIS
  • Active Ingredient(s): Letermovir
  • Strength: 240 mg, 480 mg
  • Dosage Form: Tablet;oral
  • Company: Merck Sharp Dohme
  • Approval Date: November 08, 2017
  • Submission Classification: Type 1 - New Molecular Entity
  • Indication(s): Indicated for prophylaxis of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT)
  • Approved Label: 11/08/2017 (PDF)

PREVYMIS
  • Active Ingredient(s): Letermovir
  • Strength: 240 mg/12ml, 480 mg/24ml
  • Dosage Form: Injectable;injection
  • Company: Merck Sharp Dohme
  • Approval Date: November 08, 2017
  • Submission Classification: Type 1 - New Molecular Entity
  • Indication(s): Indicated for prophylaxis of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT)
  • Approved Label: 11/08/2017 (PDF)

Cinvanti (aprepitant) injectable emulsion
  • Active Ingredient(s): Aprepitant
  • Strength: 130mg
  • Dosage Form: Injectable;injection
  • Company:  Heron Theraps Inc
  • Approval Date: November 09, 2017
  • Submission Classification: Type 3 - New Dosage Form
  • Indication(s): Indicated in adults, in combination with other antiemetic agents, for the prevention of:
    • acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin
    • nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC)
  • Approved Label: 11/09/2017 (PDF) 

ABILIFY MYCITE
  • Active Ingredient(s): Aripiprazole
  • Strength: 2 mg |  5 mg | 10 mg | 15 mg | 20 mg | 30mg
  • Dosage Form: Oral with sensor tablet
  • Company: Otsuka Pharm Co Ltd
  • Approval Date: November 13, 2017
  • Submission Classification: Type 4 - New Combination
  • Indication(s): Indicated for
    • Treatment of adults with schizophrenia
    • Treatment of bipolar I disorder
      • Acute treatment of adults with manic and mixed episodes as monotherapy and as adjunct to lithium or valproate
      • Maintenance treatment of adults as monotherapy and as adjunct to lithium or valproate
    • Adjunctive treatment of adults with major depressive disorder (MDD)
  • Approved Label: 11/13/2017 (PDF)

TEKTURNA
  • Active Ingredient(s): Aliskiren
  • Strength: 37.5 mg
  • Dosage Form: Oral pellets
  • Company: Noden Pharma
  • Approval Date: November 14, 2017
  • Submission Classification: Type 3 - New Dosage Form
  • Indication(s): Indicated for the treatment of hypertension in adults and children 6 years of age and older, to lower blood pressure
  • Approved Label: 11/14/2017 (PDF)

FASENRA
  • Active Ingredient(s): Benralizumab
  • Strength: 30 mg/mL
  • Dosage Form: Injectable;injection
  • Company: Astrazeneca AB
  • Approval Date: November 14, 2017
  • Submission Classification: Not available
  • Indication(s): Indicated for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype
  • Approved Label: 11/14/2017 (PDF)

MEPSEVII
  • Active Ingredient(s): Vestronidase alfa-VJBK
  • Strength: 10 mg / 5 ml
  • Dosage Form: Injectable;injection
  • Company: Ultragenyx Pharm Inc
  • Approval Date: November 15, 2017
  • Submission Classification: Not available
  • Indication(s): Indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis type VII (MPS VII, Sly syndrome)
  • Approved Label: Not available
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 3 days ago

Individuals with moderate-to-severe plaque psoriasis may reap better long-term improvements in the severity of their condition when treated with guselkumab over secukinumab, according to findings of the phase III ECLIPSE* trial presented at the recent Inflammatory Skin Disease Summit (ISDS 2018) held in Vienna, Austria.

Jairia Dela Cruz, 11 Jan 2019
Use of standard-dose aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) appears to confer protection against the risk of endometrial cancer in overweight and obese women, according to a meta-analysis.
Elvira Manzano, 4 days ago
Treatment with two investigational, oral JAK inhibitors may be beneficial in individuals with moderate‐to‐severe alopecia areata (spot baldness), an autoimmune disease that can cause a lot of anxiety, according to an ongoing phase II study.
2 days ago
Discontinuing the use of tyrosine kinase inhibitors (TKIs) in the treatment of patients with chronic myeloid leukaemia appears to be feasible in real-life clinical practice in the context of close molecular monitoring, a study reports.